First patient treated with Clarity’s copper-64 SAR-Bombesin in breast cancer clinical trial

On July 28, 2020 Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease,reported that the first patient has been treated in the C-BOBCAT study (Copper-64 BOmbesin in Breast CAncer Trial) (Press release, Clarity Pharmaceuticals, JUL 28, 2020, View Source [SID1234562447]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The C-BOBCAT trial is a first-in-human, investigator-led clinical trial investigating 64Cu-SAR-Bombesin (SAR-BBN) in patients with hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer. The trial is led in collaboration with Associate Professor Louise Emmett, Director of Theranostics and Nuclear Medicine, at St Vincent’s Hospital in Sydney.

Bombesin is a natural homolog to the mammalian gastrin-releasing peptide, which is able to specifically bind to the gastrin-releasing peptide receptor (GRPr). GRPr is present on the membrane of most prostate, breast, ovarian and small cell lung cancers, gastrointestinal stromal tumours, and in tumoural vessels of urinary cancers. In relation to breast cancer, HR+/HER2- breast cancers make up roughly 67%1 of new breast cancer cases diagnosed each year, affecting roughly 181,000 women in 2019 in the USA2 alone, and approximately 13,000 women in Australia3.

Clarity’s Executive Chairman, Dr Alan Taylor, said, "We are excited to commence this trial as SAR-BBN is Clarity’s second product after SARTATE to enter the clinical development stage. We are looking forward to progressing this study with our collaborators at St Vincent’s Hospital in Sydney, who have been involved in some pioneering radiopharmaceutical studies in recent times. We hope that SAR-BBN will allow for Positron Emission Tomography (PET) imaging and localisation of metastatic breast cancer lesions that express GRPr, and we look forward to utilising that data to progress SAR-BBN into other diagnostic and therapeutic trials in a range of cancers that express GRPr with our ultimate goal of better treating children and adults with cancer."

References
American Cancer Society, Surveillance Research (2017)
National Cancer Institute, Cancer Stat Facts: Female Breast Cancer, View Source
Australian Government Cancer Statistics, Breast cancer in Australia statistics, View Source

Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

On July 28, 2020 Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in oncology, reported that the first patient has been dosed with CB-5339 in a Phase 1 clinical trial of patients with relapsed/refractory acute myeloid leukemia (AML) or relapsed/refractory intermediate or high-risk myelodysplastic syndrome (MDS) (Press release, Cleave Therapeutics, JUL 28, 2020, View Source [SID1234562467]). CB-5339 is a potent and selective, second-generation, oral small molecule inhibitor of VCP/p97.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to begin patient enrollment of our clinical study in AML and MDS, which marks an important milestone in evaluating the initial safety and potential therapeutic benefit of VCP inhibitors for patients with cancer," said Amy Burroughs, president and chief executive officer of Cleave. "This clinical program stems from more than a decade of research by scientists who have identified VCP/p97 as a pan-cancer core fitness target that is essential for cancer cell growth and survival."

The primary objectives of the Phase 1 study are to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of CB-5339. Additional objectives are to examine the pharmacokinetic parameters and estimate the anti-tumor effects of CB-5339. CB-5339 is administered orally for four days, followed by a three-day treatment-free period weekly in successive 28-day cycles. The trial is expected to enroll 50 to 60 patients in the United States and Australia and does not select or exclude patients based on tumor genetic profile.

"Despite several new drug approvals in the last several years, there remains an urgent need for well-tolerated, effective therapies for patients with myeloid malignancies," said Courtney DiNardo, MD, MSCE, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. "We are eager to study CB-5339 as a unique oral therapy that could benefit our AML and MDS patients – perhaps even regardless of their mutational status – by disrupting stress pathways that are critical to cancer cells."

In addition to the AML/MDS trial, the National Cancer Institute (NCI), part of the National Institutes of Health, is sponsoring a Phase 1 clinical trial with CB-5339 in solid tumors and lymphomas. For more information on both of these trials, please visit the AML/MDS study or the Solid Tumors/Lymphomas study at www.clinicaltrials.gov.

About Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Acute myeloid leukemia is a type of cancer of the blood and bone marrow, caused by mutations in the genetic material (DNA) of myeloid stem cells which result in the formation of leukemic cells. These cells, also referred to as "AML cells," cannot mature into fully functional blood cells, and they multiply uncontrollably. Nearly 20,000 newly diagnosed acute myeloid leukemia patients and 12,000 deaths are expected from AML in the U.S. this year. Myelodysplastic syndromes are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. Nearly 15,000 newly diagnosed cases of MDS are expected per year.

Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals

On July 28, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, reported the closing of a $20 million equity investment, at $4.03 per share, by Betta Pharmaceuticals (SZ300558) bringing the total received to $35M (Press release, Agenus, JUL 28, 2020, View Source [SID1234562448]). Betta is a top Chinese pharmaceutical company focusing on the development of innovative oncology therapies. The equity investment by Betta Pharmaceuticals is part of the broader immuno-oncology (I-O) partnership that Agenus and Betta Pharmaceuticals announced last month.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the partnership Agenus is also eligible to receive up to $100 million in potential milestones plus royalties on net sales. In exchange Betta received exclusive rights for the development and commercialization of balstilimab and zalifrelimab, as both monotherapies and combination therapies, excluding intravesical delivery, in greater China, including Mainland China, Hong Kong, Macau and Taiwan.

Agenus’ balstilimab (anti-PD-1) is planned for a BLA filing this year. Trials for balstilimab alone and in combination with zalifrelimab (anti-CTLA-4) have already completed accrual and follow up of all patients. The US FDA granted Fast Track designation for balstilimab alone and in combination with zalifrelimab in this indication and the molecules are eligible for US FDA Priority Review.

Guided Therapeutics Submits Clinical Study Protocol to U.S. FDA for LuViva® Advanced Cervical Scan

On July 28, 2020 Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, reported that it had submitted its protocol to FDA for a clinical study to support marketing of the LuViva Advanced Cervical Scan in the United States (Press release, Guided Therapeutics, JUL 28, 2020, https://www.businesswire.com/news/home/20200728005157/en/Guided-Therapeutics-Submits-Clinical-Study-Protocol-U.S. [SID1234562469]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under FDA’s Investigational Device Exemption guidelines, the Agency typically responds to companies in 30 days with comments or other observations regarding a study protocol. Earlier this year, the Company filed with FDA Pre-Submission documents and met with the Agency to agree on LuViva’s new indication for use and supporting clinical trial design. FDA provided written feedback based on both the Pre-submission documents and meeting minutes that provided the Company with guidance for drafting the study protocol.

According to the protocol, LuViva will be studied to assess its ability to help detect a significant number of the up to 40% to 50% cases missed at the point of biopsy because of limitations in current imaging technology. New national guidelines for cervical cancer management published in April of 2020 stress a risk based approach, a feature already included in LuViva’s AI based risk profile algorithms. Because the available technology of visually examining the cervix under magnification often cannot detect the correct area to biopsy, or at times fails to detect the disease at all, there is a strong need for a more sensitive test like LuViva to identify more women with disease so treatment can begin sooner.

"FDA has been very responsive and helpful as the new indication for use and study to support the device claims were developed," said Gene Cartwright, CEO. "We look forward to starting and completing our new study as the next major milestones in achieving FDA approval for LuViva."

Taiho Pharmaceutical Launches Anticancer Agent LONSURF® (brand name in Japan) in China for Treatment of Colorectal Cancer

On July 28, 2020 Taiho Pharmaceutical Co., Ltd. reported the launch of its anticancer agent LONSURFⓇ (brand name in Japan, trifluridine/tipiracil (FTD/TPI), development code TAS-102) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, in addition, might be treated or not able to be treated by an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy (Press release, Taiho, JUL 28, 2020, View Source [SID1234562403]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lonsurf was approved in China in August 2019 based on the results of the Phase III TERRA study on patients with refractory mCRC in Asia (China, South Korea, and Thailand). The study met the primary efficacy endpoint of statistically prolonging overall survival (OS) in patients with unresectable advanced or recurrent colorectal cancer. The drug appeared to be generally well tolerated and its toxicities were consistent with what has been previously reported.

With this launch in China, Taiho Pharmaceutical expects that Lonsurf will make a broader contribution to patients and medical institutions as a new treatment option for patients with colorectal cancer.

About the TERRA study
The TERRA study was a randomized, double-blind, placebo-controlled Phase III comparison study evaluating the efficacy and safety of orally administered TAS-102 in patients with refractory mCRC. The study enrolled 406 patients who received at least two prior regimens of standard chemotherapies for mCRC and were refractory or intolerant those chemotherapies. The study was conducted in China, South Korea, and Thailand. Patients were randomly assigned to receive either TAS-102 or placebo in order to investigate the efficacy of TAS-102. The primary objective of the TERRA study was improvement in OS versus placebo. The study was conducted under the leadership of principal researchers in China, South Korea, and Thailand. Results from TERRA study were presented at ESMO (Free ESMO Whitepaper) 2016 Congress and e-published in the Journal of Clinical Oncology in 2017*1.

About Colorectal Cancer
The number of patients with colorectal cancer in China is on the rise. It is the fifth most common cancer cause of death in China after lung cancer, gastric cancer, hepatic cancer, and esophageal cancer. It has been reported that around 250,000 people died of colorectal cancer in China in 2018.*2

About Lonsurf
Lonsurf is an oral anticancer drug, which utilizes the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines. FTD is an antineoplastic nucleoside analogue, which is incorporated directly into the DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase.

In Japan, Taiho Pharmaceutical has been marketing Lonsurf for the treatment of unresectable advanced or recurrent colorectal cancer since 2014. Since receiving FDA approval in 2015, Taiho Oncology, Inc., a U.S. subsidiary of Taiho Pharmaceutical, has been marketing Lonsurf in the United States for mCRC refractory to prior therapy.

Taiho Pharmaceutical and Servier*3 have an exclusive license agreement for the co-development and commercialization of Lonsurf in Europe and other countries outside of the United States, Canada, Mexico, and Asia. In parts of Asia outside of Japan, Lonsurf is being marketed in Taiwan and South Korea, among others, to expand the indication of the drug.

As of July 2020, Lonsurf has been approved as a treatment for advanced mCRC in 88 countries and regions worldwide. Lonsurf has been approved as a treatment for metastatic gastric cancer in the United States in February 2019, in Japan in August 2019 and in EU in September 2019, and as of July 2020, it is approved in more than 40 countries and regions worldwide.

*1 Xu, J., Kim T., Shen L., et al. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study, Journal of Clinical Oncology, 2018; 36(4): 350-358.

*2 WHO International Agency for Research on Cancer. CANCER TODAY. Colorectal cancer: Estimated number of deaths in 2018, China, both sexes, all age

View Source;mode=cancer&mode_population=who&population=900&populations=160&key=asr&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=5&group_cancer=1&include_nmsc=1&include_nmsc_other=1#collapse-group-0-3

(Accessed July 3, 2020)

*3 Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). More information: www.servier.com/en/.